Goldman Sachs Maintains Buy on Cytek Biosciences, Raises Price Target to $15
Goldman Sachs maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and raises the price target from $12 to $15.
Cytek Reports It Received CE Marking For Series Of cFluor Reagents, TBNK Kit
Clinical flow cytometry laboratories based in Europe can now purchase Cytek cFluor® CE-IVD-certified reagents for their use. Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today
Analyst Ratings for Cytek Biosciences
Over the past 3 months, 4 analysts have published their opinion on Cytek Biosciences (NASDAQ:CTKB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Goldman Sachs Maintains Buy Rating for Cytek Biosciences: Here’s What You Need To Know
Goldman Sachs has decided to maintain its Buy rating of Cytek Biosciences (NASDAQ:CTKB) and lower its price target from $14.00 to $12.00.
Shares of Cytek Biosciences are trading up 10.93% over the last 24 hours, at $8.22 per share.
Goldman Sachs Maintains Buy on Cytek Biosciences, Lowers Price Target to $12
Goldman Sachs maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and lowers the price target from $14 to $12.
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell
• Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.